Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

sulindac

A sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Sulindac Sulfoxide
US brand name:Aflodac
Clinoril
Foreign brand name:Algocetil
Apo-Sulin
Arthrocine
Artribid
Citireuma
Clisundac
Imbaral
Novo-Sundac
Reumofil
Reumyl
Sudac
Sulinol
Sulreuma
Abbreviation:SULIN
Code name:MK-231
Chemical structure:(Z)-5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid
cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search